Professor Christoph Merten | |
|---|---|
 Christoph Merten in 2021 | |
| Born | |
| Nationality | German |
| Occupation(s) | Professor and entrepreneur |
| Known for | Development of droplet-based microfluidic technologies for biomedical applications |
| Academic background | |
| Alma mater | Goethe University of Frankfurt |
| Doctoral advisor | Christian Buchholz |
| Academic work | |
| Discipline | Bioengineering |
| Sub-discipline | Droplet-based Microfluidics |
| Institutions | EPFL (École Polytechnique Fédérale de Lausanne) |
Christoph Merten is a German bio-engineer and entrepreneur; currently professor at EPFL (École Polytechnique Fédérale de Lausanne). He is an adjunct scientist at the Ludwig Institute for Cancer Research in Lausanne.[1] His research focuses on developing biomedical microfluidics technologies for drug discovery, diagnostics, and personalized therapy in cancer research.
Career
In 2005, he started a second postdoctoral appointment at the Institut de science et d'ingénierie supramoléculaires (ISIS) in Strasbourg, France.[2] He focused on droplet-based microfluidics for cellular assays and started his research group in 2007. From 2010 to 2019, he served as a group leader at the European Molecular Biology Laboratory in Heidelberg, where he established high-throughput droplet-based microfluidic screening platforms.[3]
In 2019, he was named associate professor of bioengineering at EPFL[4] and currently leads the laboratory for biomedical microfluidics (LBMM) within the School of Engineering.[5] He also holds an adjunct scientist position at the Ludwig Institute for Cancer Research's Lausanne branch.[6]
Research
His laboratory currently uses droplet-based approaches to address questions related to personalized medicine, biological screening assays, and genomics.[7] In the context of cancer therapy, this work has allowed cost-efficient screening of numerous drug combinations on tumor samples issued from patient biopsies, enabling rapid determination of personalized treatment regimens for cancer patients.[8]
Selected publications
- Clausell-Tormos, Jenifer; Lieber, Diana; Baret, Jean-Christophe; El-Harrak, Abdeslam; Miller, Oliver J.; Frenz, Lucas; Blouwolff, Joshua; Humphry, Katherine J.; Köster, Sarah; Duan, Honey; Holtze, Christian; Weitz, David A.; Griffiths, Andrew D.; Merten, Christoph A. (2008). "Droplet-Based Microfluidic Platforms for the Encapsulation and Screening of Mammalian Cells and Multicellular Organisms". Chemistry & Biology. 15 (5): 427–437. doi:10.1016/j.chembiol.2008.04.004. PMID 18482695.
- Debs, B. E.; Utharala, R.; Balyasnikova, I. V.; Griffiths, A. D.; Merten, C. A. (2012). "Functional single-cell hybridoma screening using droplet-based microfluidics". Proceedings of the National Academy of Sciences. 109 (29): 11570–11575. Bibcode:2012PNAS..10911570D. doi:10.1073/pnas.1204514109. PMC 3406880. PMID 22753519.
- Chaipan, Chawaree; Pryszlak, Anna; Dean, Hansi; Poignard, Pascal; Benes, Vladimir; Griffiths, Andrew D.; Merten, Christoph A. (2017). "Single-Virus Droplet Microfluidics for High-Throughput Screening of Neutralizing Epitopes on HIV Particles". Cell Chemical Biology. 24 (6): 751–757.e3. doi:10.1016/j.chembiol.2017.05.009. PMID 28552581.
- Shembekar, Nachiket; Hu, Hongxing; Eustace, David; Merten, Christoph A. (2018). "Single-Cell Droplet Microfluidic Screening for Antibodies Specifically Binding to Target Cells". Cell Reports. 22 (8): 2206–2215. doi:10.1016/j.celrep.2018.01.071. PMC 5842027. PMID 29466744.
- Eduati, Federica; Utharala, Ramesh; Madhavan, Dharanija; Neumann, Ulf Peter; Longerich, Thomas; Cramer, Thorsten; Saez-Rodriguez, Julio; Merten, Christoph A. (2018). "A microfluidics platform for combinatorial drug screening on cancer biopsies". Nature Communications. 9 (1): 2434. Bibcode:2018NatCo...9.2434E. doi:10.1038/s41467-018-04919-w. PMC 6015045. PMID 29934552.
References
- ↑ "Christoph Merten". EPFL.
- ↑ Geneux, Valérie (7 September 2020). "Expert in Biomedical Microfluidics Joins EPFL". EPFL.
- ↑ "Combi-seq: A leap forward for personalized cancer therapy". Medicalxpress.com.
- ↑ Engineering, School of (26 September 2019). "Nominations of Professors at the School of Engineering". EPFL.
- ↑ "Members". EPFL.
- ↑ "ADJUNCTS". Ludwig Cancer Research.
- ↑ Geneux, Valérie (25 June 2020). "Christoph Merten Co-Awarded a Major SNSF Sinergia Grant". EPFL.
- ↑ Mathur, L.; Szalai, B.; Du, N. H.; Utharala, R.; Ballinger, M.; Landry, J. J. M.; Ryckelynck, M.; Benes, V.; Saez-Rodriguez, J.; Merten, C. A. (1 August 2022). "Combi-seq for multiplexed transcriptome-based profiling of drug combinations using deterministic barcoding in single-cell droplets". Nature Communications. 13 (1): 4450. Bibcode:2022NatCo..13.4450M. doi:10.1038/s41467-022-32197-0. PMC 9343464. PMID 35915108.
External links
- Christoph Merten publications indexed by Google Scholar